In recent years, blood-based biomarkers, including bTMB, sPD-L1, sLAG-3 have been investigated as potential prognostic markers for patients with NSCLC treated with ICIs (27–29). The gene discussed is SPDL1; the disease is non-small cell lung carcinoma.